Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track AXSM with free AI briefings, catalyst countdowns, and dilution alerts.

AXSM — Axsome Therapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$319.9M Cash on Hand

35.8mo Cash Runway

10.1% Short Interest

💊 Upcoming FDA Decisions

PDUFA Date	Drug	Indication	Type	PoA
2027-05-01	—	agitation associated with dementia due to Alzheimer’	NDA	79%

PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →

🧪 Upcoming Trial Catalysts

2026-12-01 · Phase 3 — Recruiting — Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Dis
2026-12-01 · Phase 3 — Enrolling — Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
2026-12-01 · Phase 2 — Recruiting — Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
2026-12-01 · Phase 3 — Recruiting — Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfet
2027-12-01 · Phase 3 — Enrolling — A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge
2027-12-01 · Phase 3 — Recruiting — A Study to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

📊 Drug Pipeline

Drug	Indication	Phase	Status
Solriamfetol Oral Tablet	Excessive Sleepiness	PHASE4	TERMINATED
AXS-05	Major Depressive Disorder	PHASE4	RECRUITING
Solriamfetol 75 MG	Insomnia	PHASE4	COMPLETED
Solriamfetol	Excessive Daytime Sleepiness	PHASE4	COMPLETED
Bupropion	Major Depressive Disorder	PHASE4	RECRUITING
AXS-02 (oral zoledronate)	Complex Regional Pain Syndrome	PHASE3	UNKNOWN
Solriamfetol Dose B	ADHD	PHASE3	RECRUITING
Solriamfetol Dose A	ADHD	PHASE3	RECRUITING
Solriamfetol 75mg, 150 mg, or 300 mg	Binge-Eating Disorder	PHASE3	ENROLLING_BY_INVITATION
Solriamfetol 300 mg	Excessive Sleepiness	PHASE3	RECRUITING

💰 Cash Runway & Dilution Risk

AXSM holds $319.9M in cash and burns about $26.8M/quarter from operations, giving an estimated runway of 35.8 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for AXSM free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-08-07	TABUTEAU HERRIOT	Purchase	$258,553
2026-08-07	TABUTEAU HERRIOT	Sale	$0
2026-08-07	TABUTEAU HERRIOT	Purchase	$58,851
2026-08-07	TABUTEAU HERRIOT	Sale	$1.5M
2026-08-07	TABUTEAU HERRIOT	Sale	$0

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2026-04-30	—	sNDA	+14.6%	+12.9%	+21%

Browse all historical PDUFA outcomes →

Get the full AXSM picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for AXSM and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z